Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | NPY4R | P50391 | 7/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.43 |
| ▸ | NPY1R | P25929 | 5/20 | 0.43 |
| ▸ | NPY2R | P49146 | 3/20 | 0.43 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336348 | 1.00 | TRPV1 (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24029087 | 0.97 | TRPV1 (0.43) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL21754508 | 0.94 | NPY4R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL25826708 | 0.94 | NPY4R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL23815045 | 0.94 | CHRND (0.44) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22746602 | 0.93 | TRPV1 (0.42) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24496495 | 0.93 | TRPV1 (0.45) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22702633 | 0.91 | TRPV1 (0.38) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24496677 | 0.91 | TRPV1 (0.43) | TRPV1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22702533 | 0.91 | NPY5R (0.47) | TRPV1NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | REGENERON PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | TRPV1 4706/4885NPY4R 4828/4885NPY5R 4781/4885 |
| US-20210379195-A1 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | CD81, CD2, CD44 | TRPV1 4358/4885NPY4R 4767/4885NPY5R 4398/4885 |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD40LG, CD44, CD74 | TRPV1 4397/4885NPY4R 2282/4885NPY5R 3252/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | TRPV1 4578/4885NPY4R 4454/4885NPY5R 4027/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | TRPV1 4279/4885NPY4R 4272/4885NPY5R 3915/4885 |
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | TRPV1 4706/4885NPY4R 4828/4885NPY5R 4781/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | TRPV1 4195/4885NPY4R 4745/4885NPY5R 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.